Arctic Bioscience – Q1 2024 Operational update – Progress according to plan
Highlights Q1 2024: · The HeROPA clinical trial fully recruited in January 2024, and further development is proceeding as planned · Available liquidity end of Q1 2024 of NOK 74,6 million · Above 90 % of the total nutra 2023-revenues already secured in 2024 via sales and received purchase orders · Strong growth in the Norwegian Romega market in Q1 2024The HeROPA clinical trial was fully recruited in January 2024. Since then, the clinical trial has progressed according to plan towards 6 months primary end points read-out in second half of 2024. “As the time for read-out is